Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial

Hypertension Research

Volumn 36, Issue 12, 2013, Pages 1088-1095

  Umemoto, Seiji ^a   Ogihara, Toshio ^b,c   Rakugi, Hiromi ^c   Matsumoto, Masayasu ^d   Kitagawa, Kazuo ^c   Shimada, Kazuyuki ^e   Higaki, Jitsuo ^f   Ito, Sadayoshi ^g   Suzuki, Hiromichi ^h   Ohashi, Yasuo ⁱ   Saruta, Takao ^j   Matsuzaki, Masunori ^k  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^b MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e Shin Oyama City Hospital   (Japan)

^f EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k YAMAGUCHI UNIVERSITY   (Japan)

more..

Author keywords

adrenergic antagonists; angiotensin antagonists; antihypertensive therapy diuretics; calcium channel blockers; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STROKE RISK; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BLOOD PRESSURE; BRAIN ISCHEMIA; DIHYDROPYRIDINES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; INTRACRANIAL HEMORRHAGES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK FACTORS; STROKE; SURVIVAL ANALYSIS; VASODILATOR AGENTS;

EID: 84890032953     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.100     Document Type: Article

References (33)

1. Gardener H, Rundek T, Wright CB, Elkind MS, Sacco RL. Dietary sodium and risk of stroke in the northern Manhattan study. Stroke 2012; 43: 1200-1205
2. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: The Hisayama study. Stroke 2003; 34: 2349-2354
3. Miura K, Nakagawa H, Ohashi Y, Harada A, Taguri M, Kushiro T, Takahashi A, Nishinaga M, Soejima H, Ueshima H, Japan Arteriosclerosis Longitudinal Study G. Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women: A meta-Analysis of 16 cohort studies. Circulation 2009; 119: 1892-1898
4. Hozawa A, Okamura T, Murakami Y, Kadowaki T, Nakamura K, Hayakawa T, Kita Y, Nakamura Y, Abbott RD, Okayama A, Ueshima H, NIPPON DATA80 Research Group. Joint impact of smoking and hypertension on cardiovascular disease and all-cause mortality in Japan: NIPPON DATA80, a 19-year follow-up. Hypertens Res 2007; 30: 1169-1175
5. Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, Miura K, Ueshima H. Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988-2004. Stroke 2010; 41: 1871-1876
6. Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, Murakami Y, Ohashi Y, Ueshima H, Imai Y, Japan Arteriosclerosis Longitudinal Study g. Stroke risk and antihypertensive drug treatment in the general population: The Japan arteriosclerosis longitudinal study. J Hypertens 2009; 27: 357-364
7. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. Blood Press 2009; 18: 308-347
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJNational Heart L, Blood Institute Joint National Committee on Prevention DE, Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572
9. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107
10. Kubo M, Kiyohara Y, Ninomiya T, Tanizaki Y, Yonemoto K, Doi Y, Hata J, Oishi Y, Shikata K, Iida M. Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology 2006; 66: 1539-1544
11. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407
12. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964
13. Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing G. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011; 13: 146-154
14. Sever PS, Messerli FH. Hypertension management 2011: Optimal combination therapy. Eur Heart J 2011; 32: 2499-2506
15. Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-Acting calcium channel blocker. J Pharmacol Sci 2006; 100: 243-261
16. Ogihara T, Matsuzaki M, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, Umemoto S, Kamiya A, Suzuki N, Kumagai H, Ohashi Y, Takishita S, Abe K, Saruta T. The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: Rationale and design. Hypertens Res 2005; 28: 331-338
17. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial. J Hypertens 2011; 29: 1649-1659
18. Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Combination therapy for hypertension in the elderly: A sub-Analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res 2012; 35: 441-448
19. Stroke-1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989; 20: 1407-1431
20. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh III E.E. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
21. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertensioñA meta-Analysis. Lancet 2005; 366: 1545-1553
22. Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, Itoh H. T-Type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010; 59: 84-95
23. Hayashi K. L-/T-Type Ca channel blockers for kidney protection: Ready for sophisticated use of Ca channel blockers. Hypertens Res 2011; 34: 910-912
24. Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M. Benidipine reduces albuminuria and plasma aldosterone in mild-To-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268-273
25. Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M. The L-, N-, and T-Type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 2010; 635: 49-55
26. Fuji Y, Suzuki H, Katsumata H, Nakajima S, Saruta T. Hormonal and renal responses to oral once-daily calcium entry blocker in normotensive and hypertensive persons. J Cardiovasc Pharmacol 1988; 11: 438-443
27. Sica DA. Current concepts of pharmacotherapy in hypertension: Thiazide-Type diuretics: Ongoing considerations on mechanism of action. J Clin Hypertens (Greenwich) 2004; 6: 661-664
28. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: A systematic review. Stroke 2011; 42: 2860-2865
29. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375: 938-948
30. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-Analysis. Lancet 2010; 375: 906-915
31. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke MInvestigators C, Anglo-Scandinavian Cardiac Outcomes Trial I, Committee CS, Writing C. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225
32. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Group LS. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003
33. Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: Achieve blood pressure goals. J Clin Hypertens 1999; 1: 141-147